Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Status:
Open
Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR
NCT#03191149
EA5162 is reopened to accrual, effective December 20, 2022.
